By volume, Augmentin was way higher than Mounjaro with 5,784 units sold during October, compared to just 85 units sale of ...

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

If successful in the Phase III trial, VK2735 would enter direct competition with established dual agonists such as Eli Lilly’s tirzepatide.

The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...

Over the past couple of years, Eli Lilly (NYSE: LLY) has emerged as the leader in the weight loss market. The company's ...

Eli Lilly (NYSE: LLY) is preparing to start Phase III trials of its experimental obesity therapy eloralintide by year-end, following Phase II results that showed weight reductions of up to 20% over 48 ...

People buying the peptide retatrutide online could suffer from side-effects ranging from nausea to pancreatitis ...

The starting dose of 0.25 mg will now cost Rs 2,712 per week, down from Rs 4,336 earlier, with the new prices effective ...

Celebrity endorsements by Elon Musk and Serena Williams have pushed weight loss medication into the mainstream. Demand is so ...

Eli Lilly has raised the stakes in the obesity market with midstage data for an amylin-targeting drug, eloralintide, that ...

Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...

Eli Lilly's performance over the past year hasn't been as strong as usual. The company's growth prospects justify its higher-than-average valuation. Lilly is also a terrific dividend stock. 10 stocks ...